Aura Biosciences Announces Participation at Upcoming Investor Conferences

CAMBRIDGE, Mass.–(BUSINESS WIRE)–Aura Biosciences, a leader in the development of novel targeted therapies in ocular oncology, today announced that members of Aura’s executive team will participate in the following upcoming investor conferences:

• Canaccord Genuity’s 39^th Annual Growth Conference on August 8, 2019 in Boston, MA and will present at 2:00 p.m. Eastern Time
• BTIG Biotechnology Conference on August 12, 2019 in New York, NY

About Aura Biosciences

Aura Biosciences is developing a new class of therapies to selectively target and destroy cancer cells. Its lead program, AU-011 for the treatment of primary choroidal melanoma, is being developed under a CRADA with the National Cancer Institute (NCI), part of the National Institutes of Health. For more information, visit www.aurabiosciences.com.

Contacts

Media:

David Rosen

Argot Partners

212.600.1902 | [email protected]

Investors:

Joseph Rayne

Argot Partners

617.340.6075 | [email protected]